Skip to main content

Want a detailed portfolio tracker?

KYMR
NASDAQ
$111.06

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Website: https://www.kymeratx.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Buy
Target: $125.14 (+12.68%)

Market Cap

$9.38B

Free Cash Flow Yield

-2.60%

Beta (5Y)

1.52

Price Chart

Valuation
Market Cap$9.38B
P/S182.36
P/B5.99
Profitability
Total Revenue (TTM)$51M
Gross Profit (TTM)-$283M
EBITDA-$351M
Operating Margin-244.9%
EPS-$4.14
Financial Health
Free Cash Flow Yield-2.60%
Growth & Risk
Revenue 5Y CAGR+0.86%
Beta (5Y)1.52
Sharpe Ratio1.60